Carregant...
BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
BRAF(V600E) is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop d...
Guardat en:
| Publicat a: | Int J Mol Sci |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8198461/ https://ncbi.nlm.nih.gov/pubmed/34072194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22115744 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|